One potential oversight by your physician when prescribing medications may lie within your DNA.
A recent study released on Wednesday in Science Translational Medicine revealed that almost 25% of participants had been given medications that could have been replaced or adjusted based on their genetic profiles.
The investigation, spearheaded by scientists from the University of Pittsburgh, focused on 16 genes that influence how the body reacts to drugs.
DNA samples from 98,590 individuals enrolled in the National Institutes of Health’s All of Us Research Program were examined and correlated with their medical histories when available.
Each participant possessed at least one significant genetic variation that could impact their response to specific medications, with the average participant showing nine variations. Among those with both genetic and clinical information, 24.4% had received at least one prescription that, according to genetic guidelines, should have been substituted with a different drug or adjusted in dosage.
However, this study did not assess whether patients faced adverse effects or if the efficacy of their medications was compromised due to their genetic composition.
Dr. Philip Empey, a senior author and associate professor at the University of Pittsburgh School of Pharmacy, asserts that understanding a patient’s genetic makeup could minimize the trial-and-error approach often seen in medical treatments.
“Any means we can employ to more accurately predict, from the outset, the optimal medications and dosages, will significantly reduce that trial and error,” he remarked.

A pharmacist organizes medications at a pharmacy in Vancouver in October 2022. Genetic variations can influence patients’ reactions to specific medications, which may necessitate alterations in dosage or the prescription of alternative drugs. (Darryl Dyck/The Canadian Press)
Choosing the appropriate medication
Omeprazole and pantoprazole for acid reflux, along with atorvastatin for cholesterol management, were among the frequently prescribed medications for participants whose genetic profiles indicated modifications in treatment could be beneficial.
Empey notes that certain genetic variations may heighten the likelihood of muscle complications when patients take statins like atorvastatin, which are intended to lower the risk of heart attacks or strokes.
This information could aid physicians in selecting alternative medications or adjusting existing treatments.
“It empowers clinicians to make more informed choices, such as, ‘Perhaps we should avoid that cholesterol drug. Maybe we initiate treatment at a lower dose. Perhaps there’s a ceiling dose we should adhere to, or we should monitor specific toxicities more closely,'” Empey explained.
In some instances, the implications can be more severe.
Experts consulted by CBC News indicated that genetic testing can pinpoint patients who may not respond effectively to clopidogrel (Plavix), a medication used to avert blood clots after cardiac stenting, thus enabling doctors to opt for alternative therapies.

Dr. James Kennedy, who leads the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health, states that genetic testing can assist physicians in selecting medications, but other factors, like diet, lifestyle, and any current medications, must also be considered. (CBC)
A guideline, not a certainty
Dr. James Kennedy remarked that the findings of the study were expected, but he was particularly impressed by the genetic diversity and inclusion of individuals of African descent.
His team has conducted genetic tests for about 11,000 patients, many of whom had previously tried two or three antidepressants without achieving satisfactory outcomes.
Approximately 8 to 10 percent of individuals metabolize certain commonly prescribed antidepressants at an unusually slow rate, leading to medication build-up and potential side effects, he explained.
According to Kennedy, genetic testing proves particularly beneficial for patients who have already faced challenges with multiple medications.
Nonetheless, he emphasized that DNA testing alone cannot predict a patient’s reaction to a specific medication. Factors such as other drugs the patient is taking, smoking habits, and diet must also be factored in.
“We provide a blueprint of tendencies, but it is essential to discuss all other considerations before making a final decision,” he noted.
A 2023 European clinical trial cited in the study indicated that genetic testing prior to prescribing certain drugs can decrease adverse drug reactions. However, making such testing a standard practice in Canada poses challenges.

A researcher at the University of Calgary holds a diagnostic kit used for identifying genetic variations in February 2024. While such testing could aid doctors in customizing medications for individual patients, cost and practical issues have restricted its widespread adoption in Canada. (Jeff McIntosh/The Canadian Press)
Barriers to widespread testing in Canada
Dr. Jacob Udell, a cardiologist in Toronto, commented on the study’s impressive nature, particularly due to the genetic diversity among participants, but noted that few healthcare providers in Canada or the U.S. consistently assess patients for genetic variations that influence drug metabolism.
“This is not typically a priority for front-line clinicians,” he stated.
Udell explained that in many cases, doctors can prescribe a medication, observe how the patient responds, and make necessary adjustments without significant consequences. This method can often be more feasible than routinely screening for genetic variations.
He also raised concerns regarding whether widespread genetic testing should take precedence when Canada’s healthcare system is grappling with the need for more fundamental services.
“Our focus is on ensuring everyone has access to a family doctor,” he remarked.
In addition to the financial aspects of testing, Udell pointed out that clinicians would require access to genetic testing results and the knowledge to interpret them effectively.
Empey concurred that integrating genetic testing into routine practice would necessitate considerable investment in training, infrastructure, and new systems to facilitate result-sharing among healthcare providers.
“The scientific backing for many medications is robust. The challenge of implementation, however, is largely economic, procedural, and educational,” he stated.
For the time being, Empey advises patients to inquire with their doctors or pharmacists about the potential benefits of genetic testing and to share any relevant results.
Udell cautioned that private testing may become more prevalent among those who can afford it, “but this won’t assist those who cannot bear the costs of testing.”